|
1
|
Ries LAG, Melbert D, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2004. National Cancer
Institute; Bethesda, MD: 2007, http://seer.cancer.gov/archive/csr/1975_2004/.
Accessed April 6, 2009
|
|
2
|
Jenkinson F and Steele RJ: Colorectal
cancer screening - methodology. Surgeon. 8:164–171. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mittag F, Kuester D, Vieth M, et al: DAPK
promotor methylation is an early event in colorectal
carcinogenesis. Cancer Lett. 240:69–75. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee BB, Lee EJ, Jung EH, et al: Aberrant
methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a
biomarker for early detection of colorectal cancer. Clin Cancer
Res. 15:6185–6191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang DR and Tang D: Hypermethylated SFRP2
gene in fecal DNA is a high potential biomarker for colorectal
cancer noninvasive screening. World J Gastroenterol. 14:524–531.
2008. View Article : Google Scholar
|
|
6
|
Pehlivan S, Artac M, Sever T, et al: Gene
methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations
in sporadic colorectal cancer. Cancer Genet Cytogenet. 201:128–132.
2010. View Article : Google Scholar
|
|
7
|
Hellebrekers DM, Lentjes MH, van den Bosch
SM, et al: GATA4 and GATA5 are potential tumor suppressors and
biomarkers in colorectal cancer. Clin Cancer Res. 15:3990–3997.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rojas A, Meherem S, Kim YH, et al: The
aberrant methylation of TSP1 suppresses TGF-beta1 activation in
colorectal cancer. Int J Cancer. 123:14–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu W, Guan M, Su B, et al: Rapid
determination of AKAP12 promoter methylation levels in peripheral
blood using methylation-sensitive high resolution melting (MS-HRM)
analysis: Application in colorectal cancer. Clin Chim Acta.
411:940–946. 2010. View Article : Google Scholar
|
|
10
|
Ying J, Li H, Yu J, et al: WNT5A exhibits
tumor-suppressive activity through antagonizing the
Wnt/beta-catenin signaling, and is frequently methylated in
colorectal cancer. Clin Cancer Res. 14:55–61. 2008. View Article : Google Scholar
|
|
11
|
Chen WD, Han ZJ, Skoletsky J, et al:
Detection in fecal DNA of colon cancer-specific methylation of the
nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lenhard K, Bommer GT, Asutay S, et al:
Analysis of promoter methylation in stool: a novel method for the
detection of colorectal cancer. Clin Gastroenterol Hepatol.
3:142–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Azuara D, Rodriguez-Moranta F, de Oca J,
et al: Novel methylation panel for the early detection of
colorectal tumors in stool DNA. Clin colorectal cancer. 9:168–176.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petko Z, Ghiassi M, Shuber A, et al:
Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in
fecal DNA from patients with colorectal polyps. Clin Cancer Res.
11:1203–1209. 2005.PubMed/NCBI
|
|
15
|
Abbaszadegan MR, Tavasoli A, Velayati A,
et al: Stool-based DNA testing, a new noninvasive method for
colorectal cancer screening, the first report from Iran. World J
Gastroenterol. 13:1528–1533. 2007. View Article : Google Scholar
|
|
16
|
Müller HM, Oberwalder M, Fiegl H, et al:
Methylation changes in faecal DNA: a marker for colorectal cancer
screening? Lancet. 363:1283–1285. 2004.PubMed/NCBI
|
|
17
|
Grady WM, Rajput A, Lutterbaugh JD and
Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA
in the serum of patients with microsatellite unstable colon cancer.
Cancer Res. 61:900–902. 2001.PubMed/NCBI
|
|
18
|
Tallen G, Kaiser I, Krabbe S, et al: No
ING1 mutations in human brain tumours but reduced expression in
high malignancy grades of astrocytoma. Int J Cancer. 109:476–479.
2004. View Article : Google Scholar
|
|
19
|
Nouman GS, Anderson JJ, Crosier S, et al:
Downregulation of nuclear expression of the p33ING1b
inhibitor of growth protein in invasive carcinoma of the breast. J
Clin Pathol. 56:507–511. 2003.PubMed/NCBI
|
|
20
|
Oki E, Maehara Y, Tokunaga E, et al:
Reduced expression of p33(ING1) and the relationship with p53
expression in human gastric cancer. Cancer Lett. 147:157–162. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen L, Matsubara N, Yoshino T, et al:
Genetic alterations of candidate tumor suppressor ING1 in human
esophageal squamous cell cancer. Cancer Res. 61:4345–4349.
2001.
|
|
22
|
Shen DH, Chan KY, Khoo US, et al:
Epigenetic and genetic alterations of p33ING1b in
ovarian cancer. Carcinogenesis. 26:855–863. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gunduz M, Ouchida M, Fukushima K, et al:
Genomic structure of the human ING1 gene and tumor-specific
mutations detected in head and neck squamous cell carcinomas.
Cancer Res. 60:3143–3146. 2000.
|
|
24
|
Olek A, Oswald J and Walter J: A modified
and improved method for bisulphite based cytosine methylation
analysis. Nucleic Acids Res. 24:5064–5066. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Sun D, Van do N, et al:
Inactivation of RASSF2A by promoter methylation correlates with
lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer.
120:32–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akobeng AK: Understanding diagnostic tests
1: sensitivity, specificity and predictive values. Acta Paediatr.
96:338–341. 2007. View Article : Google Scholar
|
|
27
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
|
|
28
|
Huang ZH, Li LH, Yang F and Wang JF:
Detection of aberrant methylation in fecal DNA as a molecular
screening tool for colorectal cancer and precancerous lesions.
World J Gastroenterol. 13:950–954. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herman JG, Graff JR, Myöhänen S, et al:
Methylation-specific PCR: a novel PCR assay for methylation status
of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang J, Yang SB, Xie Y, et al: Detection
of methylated tissue factor pathway inhibitor 2 and human long DNA
in fecal samples of patients with colorectal cancer in China.
Cancer Epidemiol. 36:73–77. 2012. View Article : Google Scholar
|
|
31
|
Grunau C, Clark SJ and Rosenthal A:
Bisulfite genomic sequencing: systematic investigation of critical
experimental parameters. Nucleic Acids Res. 29:e652001. View Article : Google Scholar
|
|
32
|
Palmisano WA, Divine KK, Saccomanno G, et
al: Predicting lung cancer by detecting aberrant promoter
methylation in sputum. Cancer Res. 60:5954–5958. 2000.
|
|
33
|
Mandel JS, Bond JH, Church TR, et al:
Reducing mortality from colorectal cancer by screening for fecal
occult blood. Minnesota colon cancer control study. N Engl J Med.
328:1365–1371. 1993. View Article : Google Scholar
|
|
34
|
Heresbach D, Manfredi S, D’Halluin PN, et
al: Review in depth and meta-analysis of controlled trials on
colorectal cancer screening by faecal occult blood test. Eur J
Gastroenterol Hepatol. 18:427–433. 2006. View Article : Google Scholar
|
|
35
|
Imperiale TF, Ransohoff DF, Itzkowitz SH,
et al: Fecal DNA versus fecal occult blood for colorectal-cancer
screening in an average-risk population. N Engl J Med.
351:2704–2714. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Collins JF, Lieberman DA, Durbin TE, et
al: Accuracy of screening for fecal occult blood on a single stool
sample obtained by digital rectal examination: a comparison with
recommended sampling practice. Ann Intern Med. 142:81–85. 2005.
View Article : Google Scholar
|
|
37
|
Nadel MR, Shapiro JA, Klabunde CN, et al:
A national survey of primary care physicians’ methods for screening
for fecal occult blood. Ann Intern Med. 142:86–94. 2005.
|
